Academic Journal
Προβολή σε EDS

Continued decitabine/all-trans retinoic acid treatment: extended complete remission in an elderly AML patient with multi-hit TP53 lesions and complex-monosomal karyotype

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Continued decitabine/all-trans retinoic acid treatment: extended complete remission in an elderly AML patient with multi-hit TP53 lesions and complex-monosomal karyotype
Συγγραφείς: Thomas, Johanna, Rehman, Usama-Ur, Bresser, Helena, Grishina, Olga, Pfeifer, Dietmar, Sollier, Etienne, Döhner, Konstanze, Plass, Christoph, Becker, Heiko, Schmoor, Claudia, de Wit, Maike, Lübbert, Michael
Πηγή: http://lobid.org/resources/99370675582406441#!, 16(1):126.
Έτος έκδοσης: 2024
Συλλογή: Publisso (ZB MED-Publikationsportal Lebenswissenschaften)
Θεματικοί όροι: Female [MeSH], Mutation [MeSH], Aged, 80 and over [MeSH], Humans [MeSH], Tumor Suppressor Protein p53/genetics [MeSH], Karyotype [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Decitabine/therapeutic use [MeSH], Brief Report, Tretinoin/therapeutic use [MeSH], Male [MeSH], Leukemia, Myeloid, Acute/genetics [MeSH], Remission Induction/methods [MeSH], Decitabine/administration, Acute/drug therapy [MeSH]
Περιγραφή: AbstractDNA-hypomethylating agents (HMAs) induce notable remission rates in AML/MDS patients withTP53mutations; however, secondary resistance often develops rapidly. In the DECIDER trial (NCT00867672), elderly AML patients (also those with adverse genetics) randomized to all-transretinoic acid (ATRA) added to decitabine (DEC) attained significantly delayed time-to-resistance. An 82-year-old patient with a non-disruptive, in-frameTP53mutation (p.Cys238_Asn239delinsTyr, VAF 90%) and complex-monosomal karyotype attained a complete hematologic and cytogenetic remission with DEC + ATRA, with 3.7 years survival after 30 treatment cycles that were well-tolerated. Further HMA + ATRA studies appear warranted in AML/MDS patients of different genetic risk groups ineligible for more intensive treatment.Trial registration: This trial was registered at ClinicalTrials.gov identifier: NCT00867672
Τύπος εγγράφου: article in journal/newspaper
Γλώσσα: English
Relation: https://repository.publisso.de/resource/frl:6523596; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11391765/
DOI: 10.1186/s13148-024-01737-4
Διαθεσιμότητα: https://repository.publisso.de/resource/frl:6523596
https://doi.org/10.1186/s13148-024-01737-4
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11391765/
Rights: https://creativecommons.org/licenses/by/4.0/
Αριθμός Καταχώρησης: edsbas.2682165D
Βάση Δεδομένων: BASE
Περιγραφή
DOI:10.1186/s13148-024-01737-4